Rigel to Present at the 20th Annual Global Investment Conference in New York City Aug 29, 2018 7:30am EDT
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update Aug 08, 2018 4:07pm EDT
Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results Aug 01, 2018 7:30am EDT
Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases Jun 26, 2018 7:30am EDT
Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA Jun 12, 2018 7:30am EDT
Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. May 29, 2018 7:30am EDT
